Biography
\r\nIrsida Mehmeti has completed her PhD at the age of 30 years from Catholic University “Our Lady of Good Counsel†in Albania. She is a young researcher and lecturer at the department of Pharmaceutical Sciences in the faculty of Pharmacy of the same University. She has published different publications in important scientific journals\r\n
Abstract
Adverse Events following Immunisation are becoming day after day an increasing concern all over the world. Different countries have implemented various post-vaccination surveillance systems to detect, treat and prevent AEFI. Geographical variations in AE reporting are a known phenomenon. The main objective of this study is to confront the nature, design and performance of AEFI surveillance system in Albania with other countries extracting various indicators from studies found in the literature and confronting them with those obtained by the analysis of the AEFI database of Albania in order to highlight differences and similarities. Through a systematic review of published studies which documented the AEFI rates in different countries at regional or national level, a total of 31 articles were chosen for full reading of the content. The overall reporting rates were calculated differently in various countries. In some of them, distributed doses were taken as numerator, in some others the type was not specified and only in few of them administered doses were used. Albania has the lowest reporting rate of all countries and regions reviewed. Serious events in Albania represented about 21% of all reported AEFI cases. This number were close to that of Switzerland which had the same percentage of serious events. The patterns of AEFI in Albania were close to the patterns of AEFI in other countries with similar surveillance system. The completeness and accuracy of information in the Albanian vaccine safety surveillance system still needs to improve.
Biography
Wallace M Macindoe has completed his PhD from the University of Kent and also has completed his MBA from Durham University Business School, UK. He has held several positions in academia as well as in the pharmaceutical industry before founding his own consultancy company “i3 Consultâ€.\r\n\r\n
Abstract
Due to interplay of pressures which are political, economic, social, technological and environmental, the financial burden for maintaining a public health budget continues unabated throughout the world. We can segment the stakeholders of public health into four distinct areas-prescribers e.g. healthcare professionals and the affiliated infrastructure, payers e.g. health insurance schemes and government subsidization, patients, for public health this includes healthy individuals, and lastly pharma, e.g. pharmaceutical, biotechnology and other life science organizations which through their commitment to R&D seek to improve public health outcomes albeit in most cases for their own financial gain. Highlighted here are the key elements which one particular segment, Pharma, needs to address in order to drive efficiencies and cut costs as a commercial player in public health provision. In assessing the operational efficiencies of a Pharma organization, it is important to conduct a value chain analysis. There are also critical success factors which need to be assessed in drug discovery, development and clinical trial management operations. For the manufacturing operations, scrutiny of SOPs, integration of high end technology is important. At the distribution level, targeting emerging markets with high potential, speed-to-market for NCE launches and response times for recalls and demand spikes are some high priority considerations. For efficiency gains in sales and marketing operations of pharma, technology needs to be implemented that enables not only content and messaging to be edited according to the patient and physician needs but also to have built-in compliance workflows.\r\n\r\n